Combination effects of tamoxifen plus 5-fluorouracil on gastric cancer cell lines in vitro
| Autor: | Eiji Kobayashi, Yasuhiko Kitoh, Ryugo Okabe, Yoshinori Hosoya, Kyotaro Kanazawa, Akio Fujimura |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Cancer Research
medicine.medical_specialty Time Factors Combination therapy medicine.medical_treatment Estrogen receptor Biology Adenocarcinoma Stomach Neoplasms Transforming Growth Factor beta Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Tumor Cells Cultured Humans Secretion skin and connective tissue diseases Cytotoxicity Chemotherapy Dose-Response Relationship Drug medicine.disease Tamoxifen Endocrinology Oncology Receptors Estrogen Cancer research Fluorouracil Carcinoma Signet Ring Cell Cell Division medicine.drug |
| Zdroj: | Cancer letters. 140(1-2) |
| ISSN: | 0304-3835 |
| Popis: | We tested the effect of tamoxifen alone and tamoxifen plus 5-fluorouracil (5-FU) on proliferation of two different types of gastric cancer cell lines using the WST-1 method. A high dose of tamoxifen suppressed the proliferation of KATOIII cells (poorly differentiated adenocarcinoma), but MKN28 cells (well-differentiated adenocarcinoma) were not affected. The combination of the two drugs resulted in a synergistic anti-proliferative activity on KATOIII cells. On the other hand, in the combination therapy, tamoxifen stimulated MKN28 cells to proliferate in a dose-dependent manner. TGF-beta1 secretion was not changed in KATOIII cells by tamoxifen plus 5-FU treatment but was down-regulated in MKN28 cells. Both cancer cell lines were judged as intracellular estrogen receptor (ER) negative. These data suggest that the anti-proliferative effects of tamoxifen plus 5-FU on KATOIII cells were not dependent on ER expression or TGF-beta1 secretion. On the other hand, their proliferative effects on MKN28 cells might be, in part, caused by the reduced secretion of TGF-beta1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect